新辅助布罗利祖马布在三阴性乳腺癌中的使用趋势
Ellen Li1, Samantha R Spierling Bagsic2, Rebecca F Belasco2
1Department of Biology, Cornell University, Ithaca, NY.
American journal of clinical oncology
|February 24, 2026
概括
在三阴性乳腺癌 (TNBC) 的新辅助化疗中使用 pembrolizumab 的比例很高,并在全国范围内不断增加. 然而,社会经济贫困地区的患者的采用率较低,突出了癌症治疗可获得性的差异.
科学领域:
- 在瘤学瘤学.
- 医疗保健服务研究 医疗服务研究
- 药物经济学 药物经济学
背景情况:
- 与新辅助化疗 (NAC) 结合的布罗利祖马布已证明对三阴性乳腺癌 (TNBC) 的疗效有所改善.
- 了解NAC-pembrolizumab批准后的现实世界采用模式对于评估治疗可访问性至关重要.
研究的目的:
- 评估使用新辅助化疗与 pembrolizumab 治疗 TNBC 的国家趋势.
- 检查患者人口统计和社会经济地位对采用这种治疗方案的影响.
主要方法:
- 对2021年至2024年期间接受NAC的TNBC患者的Epic Cosmos数据库的分析.
- 佩布罗利祖马布使用与患者的种族/种族和区域贫困指数 (ADI) 得分的相关性.
主要成果:
- 在6689名符合条件的TNBC患者中,布罗利祖马布的总体使用率达到76.2%,同比大幅增加.
- 没有发现基于种族或种族的使用差异.
- 居住在ADI得分最高的地区的患者使用布罗利祖马布的比例明显较低 (74.0%对比77.4%,P=0.04).
结论:
- 在批准后不久,在TNBC治疗中观察到布罗利祖马布的高国家采用率.
- 虽然种族和种族与治疗使用没有相关性,但ADI指出的社会经济因素在获得治疗方面发挥了作用.
- 研究结果表明,对于先进癌症治疗的采用,存在潜在的社会经济障碍.
更多相关视频
相关概念视频
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K